AR045793A1 - Compuestos derivados de 3-heterociclil-indol - Google Patents
Compuestos derivados de 3-heterociclil-indolInfo
- Publication number
- AR045793A1 AR045793A1 ARP040103394A ARP040103394A AR045793A1 AR 045793 A1 AR045793 A1 AR 045793A1 AR P040103394 A ARP040103394 A AR P040103394A AR P040103394 A ARP040103394 A AR P040103394A AR 045793 A1 AR045793 A1 AR 045793A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- heterocyclic group
- group
- heteroatoms independently
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 102000001267 GSK3 Human genes 0.000 abstract 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
Abstract
Compuestos, proceso para su preparación, intermediarios utilizados en el mismo, formulaciones farmacéuticas que contienen dichos compuestos terapéuticamente activos y uso de dichos compuestos activos en terapia para la prevención y tratamiento de trastornos asociados con la glucógeno sintasa quinasa-3 (GSK-3). Reivindicación 1: Un compuesto que tiene la fórmula 1a o 1b en las cuales: P representa un anillo heteroaromático de 5 o 6 miembros que contiene uno o dos heteroátomos seleccionados independientemente entre N, O, y S, de los cuales por lo menos un heteroátomo es N; R1 es H, R2 es seleccionado entre: alquilo C1-6, ciano, halógeno, (CO)OR10 y CONR10R11; R3 es seleccionado entre alquilo C1-6, ciano, nitro, (CO)OR4, alquil C1-6- NR4R5, Oalquil C2-6-NR4R5, CONR4R5, SO2R4, OSO2R4 y (SO2)NR4R5; R4 es seleccionado entre H, CF3 y alquilo C1-6; R5 es seleccionado entre H, alquilo C1-6, alquil C1-6-NR6R7 y, donde R4 y R5 pueden formar juntos un grupo heterocíclico de 4, 5, 6 o 7 miembros que contiene uno o más heteroátomos seleccionados independientemente entre N, O y S, donde dicho grupo heterocíclico puede estar optativamente sustituido con el grupo Y; R6 y R7 son independientemente seleccionados entre H, alquilo c1-6, (CO)alquilo C1-6 y donde R6 y R7 pueden formar juntos un grupo heterocíclico de 5 o 6 miembros que contiene uno o más heteroátomos seleccionados independientemente entre N, O y S, donde dicho grupo heterocíclico puede estar optativamente sustituido con el grupo Y; R8 y R9 son independientemente seleccionados entre H y alquilo C1-6 y donde R8 y R9 pueden formar juntos un grupo heterocíclico de 5 o 6 miembros que contiene uno o más heteroátomos seleccionados independientemente entre N, O, y S; R10 es seleccionado entre H y alquilo C1-6; R11 es seleccionado entre H, alquilo C1-6, alquil C1-6CN, alquilarilo C0-6, alquil C2-6OR8, alquil C1-6(CO)NR6R7, alquil C1-6(SO2)R6, alquil C1-6(SO2)NR6R7, alquilheteroarilo C0-6, un grupo alquil C0- 6heterocíclico C3-6 y alquilo C1-6NR6R7, y donde cualquier alquilarilo C0-6 y alquilheteroarilo C0-6 puede estar sustituido con uno o más grupos Z y donde cualquier grupo alquil C0-6heterociclico C3-6 puede estar sustituido con uno o más grupos Y; Z es seleccionado entre halo, alquilo C1-6, alcoxi C1-6, OCF3 y CF3; Y es seleccionado entre oxo, alquil C2-6OR8, alquilo C1-6, alquilarilo C0-6, alquilheteroarilo C0-6, OR8 y alquilo C2-6NR8R9; m es 0, 1, 2, 3 o 4; n es 0, 1, 2, 3 o 4; en forma de base libre o sal de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302546A SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045793A1 true AR045793A1 (es) | 2005-11-16 |
Family
ID=29212538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103394A AR045793A1 (es) | 2003-09-24 | 2004-09-21 | Compuestos derivados de 3-heterociclil-indol |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7683067B2 (es) |
| EP (1) | EP1667990A2 (es) |
| JP (1) | JP2007506734A (es) |
| CN (1) | CN1886397A (es) |
| AR (1) | AR045793A1 (es) |
| AU (1) | AU2004273771B2 (es) |
| BR (1) | BRPI0414632A (es) |
| CA (1) | CA2538381A1 (es) |
| MX (1) | MXPA06003195A (es) |
| SE (1) | SE0302546D0 (es) |
| TW (1) | TW200526627A (es) |
| UY (1) | UY28528A1 (es) |
| WO (1) | WO2005027823A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| JP2009525325A (ja) * | 2006-02-02 | 2009-07-09 | アストラゼネカ・アクチエボラーグ | ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］１ｈ−インドール−５−カルボニトリルの遊離塩基又は塩としての医薬用途 |
| SA07280004B1 (ar) | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| JP2009528344A (ja) * | 2006-02-28 | 2009-08-06 | アストラゼネカ・アクチエボラーグ | インドール誘導体の新規な塩及び医薬におけるその使用 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007120102A1 (en) * | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| TW201040191A (en) * | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP2377850A1 (en) * | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| MX2013006694A (es) | 2010-12-21 | 2013-07-29 | Bayer Ip Gmbh | Procedimiento para producir oxindoles sustituidos con triazinilo. |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| WO2021243040A2 (en) * | 2020-05-29 | 2021-12-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof |
| CN119118901B (zh) * | 2024-09-09 | 2025-09-30 | 中国人民解放军北部战区总医院 | 一种氧吲哚类衍生物及其制备方法与在trpa1抑制剂方向的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5940149B2 (ja) * | 1977-11-09 | 1984-09-28 | 大塚製薬株式会社 | オキシインド−ル誘導体 |
| US5565580A (en) | 1994-01-27 | 1996-10-15 | Neurosearch A/S | Glutamate Antagonists |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| US6569868B2 (en) * | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| DE60026297T2 (de) | 1999-05-21 | 2006-11-02 | Bristol-Myers Squibb Co. | Pyrrolotriazin kinasehemmer |
| WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| YU4403A (sh) | 2000-07-27 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati 3-indolil-4-fenil-1h-pirol-2,5-diona, kao inhibitori glikogen sintaza kinaze-3 beta |
| US20020045566A1 (en) * | 2000-10-13 | 2002-04-18 | Gribkoff Valentin K. | Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| SE0104340D0 (sv) * | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| EP1458711B1 (en) | 2001-12-21 | 2007-07-18 | AstraZeneca AB | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3 |
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| MXPA04012188A (es) | 2002-06-05 | 2005-07-25 | Johnson & Johnson | Derivados de bisindolil-maleimida como inhibidores de cinasa. |
-
2003
- 2003-09-24 SE SE0302546A patent/SE0302546D0/xx unknown
-
2004
- 2004-09-15 TW TW093127911A patent/TW200526627A/zh unknown
- 2004-09-21 WO PCT/SE2004/001363 patent/WO2005027823A2/en not_active Ceased
- 2004-09-21 AR ARP040103394A patent/AR045793A1/es unknown
- 2004-09-21 AU AU2004273771A patent/AU2004273771B2/en not_active Ceased
- 2004-09-21 BR BRPI0414632-8A patent/BRPI0414632A/pt not_active IP Right Cessation
- 2004-09-21 JP JP2006527944A patent/JP2007506734A/ja active Pending
- 2004-09-21 US US10/572,778 patent/US7683067B2/en not_active Expired - Fee Related
- 2004-09-21 CN CNA2004800347007A patent/CN1886397A/zh active Pending
- 2004-09-21 MX MXPA06003195A patent/MXPA06003195A/es not_active Application Discontinuation
- 2004-09-21 CA CA002538381A patent/CA2538381A1/en not_active Abandoned
- 2004-09-21 UY UY28528A patent/UY28528A1/es not_active Application Discontinuation
- 2004-09-21 EP EP04775465A patent/EP1667990A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005027823A3 (en) | 2005-06-02 |
| US7683067B2 (en) | 2010-03-23 |
| CN1886397A (zh) | 2006-12-27 |
| US20080275041A1 (en) | 2008-11-06 |
| BRPI0414632A (pt) | 2006-11-07 |
| MXPA06003195A (es) | 2006-06-23 |
| JP2007506734A (ja) | 2007-03-22 |
| AU2004273771A1 (en) | 2005-03-31 |
| TW200526627A (en) | 2005-08-16 |
| SE0302546D0 (sv) | 2003-09-24 |
| EP1667990A2 (en) | 2006-06-14 |
| UY28528A1 (es) | 2005-04-29 |
| WO2005027823A2 (en) | 2005-03-31 |
| AU2004273771B2 (en) | 2008-11-06 |
| CA2538381A1 (en) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| AR088808A2 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| ES2058292T3 (es) | Derivados de indol. | |
| CO4940418A1 (es) | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso | |
| AR038996A1 (es) | Compuestos con efecto inhibidor sobre la gsk3, formulaciones farmaceuticas que los contienen y proceso de preparacion de los mismos | |
| AR039566A1 (es) | Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion | |
| AR032165A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de dichas carboxamidas para preparar un medicamento como agentes antivirales y el uso in vitro para inhibir una dna polimerasa viral | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| ES2132580T3 (es) | Derivados de aroil-piperidina. | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR044829A1 (es) | Derivados de bis-4-cloro fenil pirazinas | |
| AR002012A1 (es) | Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. | |
| AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| AR078201A1 (es) | Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos | |
| AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
| BR0015836A (pt) | Cristal de 4-carboxiamino-2-etil-1,2,3,4-tetra-hidroquinolina como inibidor de cetp | |
| ES2123652T3 (es) | 7-(2-aminoetil)-benzotiazolonas. | |
| AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
| AR057981A1 (es) | Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion | |
| AR009379A1 (es) | Derivados de acido piperidin-cetocarboxilico, su uso y composiciones farmaceuticas que los contienen | |
| UY27716A1 (es) | Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo. | |
| AR006360A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |